Company Overview and News


Add OSL
to your dashboard

Headline News

OncoSil Medical reveals positive data from pancreatic cancer clinical study

2017-10-23 proactiveinvestors.com.au
OncoSil Medical Ltd’s (ASX:OSL) pancreatic cancer clinical study has demonstrated significant local disease control with up to 73% reduction in tumour volume observed 4 weeks post implant.

OncoSil Medical gets ready to present pancreatic cancer clinical study data

2017-10-16 proactiveinvestors.com.au
OncoSil Medical Ltd (ASX:OSL) continues to make progress, having recruited 28 subjects into the study group of its Global Pancreatic Cancer Clinical Study Program, up from 23 patients on 22 September.

OncoSil Medical continues to advance its pancreatic cancer study

2017-09-22 proactiveinvestors.com.au
OncoSil Medical Ltd (ASX:OSL) continues to make steady progress, having recruited 23 subjects into the study group of its Global Pancreatic Cancer Clinical Study Programme.

OncoSil Medical wins key approval

2017-04-19 proactiveinvestors.com.au
OncoSil Medical (ASX:OSL) has received approval from the Institutional Review Board (IRB) of the MD Anderson Cancer Center at the University of Texas for its global clinical study program in pancreatic cancer. The approval is the final step for US hospitals to agree to participate in a clinical study and recruit and treat patients under the agreed study protocols. MD Anderson will now finalise site initiation and complete final training before first patient recruitment which is anticipated to occur in May.

Oncosil Medical attracts broker attention

2017-04-03 proactiveinvestors.com.au
Oncosil Medical (ASX:OSL) has received a Buy Recommendation and a price target of $0.38 per share from broker Wilsons.

OncoSil Medical crosses a milestone in global pancreatic cancer study

2017-03-27 proactiveinvestors.com.au
OncoSil Medical (ASX:OSL) and Monash Health has recruited the first subject for a global clinical study program of OncoSil™ device in pancreatic cancer.

OncoSil Medical outlines timeline for CE Mark

2017-02-08 proactiveinvestors.com.au
OncoSil™ is a targeted radioactive isotope (Phosphorous-32), implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound.

OncoSil Medical Ltd updates on Pancreatic Cancer Clinical Study

2016-11-28 proactiveinvestors.com.au
- Johns Hopkins Hospital and MD Anderson Cancer Centre are the leading U.S. centres; - Investigational Review Board (IRB) process has commenced and is on-going for these two U.S. centres; - Guy’s and St Thomas’ Hospitals, London are the leading UK centres; and - Monash Health has agreed to be the lead Australian centre – ethics submission filed and under review.

OncoSil Medical Ltd: Broker boosts price target

2016-11-09 proactiveinvestors.com.au
The OncoPac-1 study is set to commence recruitment in 1Q CY17 at 10 prestigious oncology centres around the world, headlined by MD Anderson (Texas) and Johns Hopkins (Baltimore).

OncoSil Medical Ltd's well-funded and delivering milestones

2016-10-28 proactiveinvestors.com.au
OncoSil is a late stage medical devices company focused on localised treatments for patients with pancreatic and liver cancer.

OncoSil Medical Ltd receives a Buy recommendation

2016-10-18 proactiveinvestors.com.au
OncoSil Medical Ltd (ASX:OSL) has received a Buy rating and $0.42 per share price target from Wilsons Research.

OncoSil Medical Ltd swells cash position after tax refund

2016-09-26 proactiveinvestors.com.au
OncoSil Medical Ltd (ASX:OSL) is developing safer and more effective ways to deliver radiation therapy to cancer patient’s tumours. The current product in development, OncoSil™, is a locally implanted medical device that emits radiation into pancreatic tumours for up to three months.

High Arctic Energy Services More Than Triples Earnings Estimates - A Post-Earnings Analysis

2016-09-19 seekingalpha
High Arctic Energy Services Inc. more than tripled earnings estimates of .04 per share, by posting .13 per share.

OncoSil Medical Ltd outlines pending board departure of Martin Rogers

2016-09-12 proactiveinvestors.com.au
OncoSil Medical Ltd (ASX:OSL) is developing safer and more effective ways to deliver radiation therapy to cancer patient’s tumours. The current product in development, OncoSil™, is a locally implanted medical device that emits radiation into pancreatic tumours for up to three months.

OncoSil Medical Ltd completes key step towards commercial sales

2016-08-18 proactiveinvestors.com.au
OncoSil Medical Ltd (ASX:OSL) is developing safer and more effective ways to deliver radiation therapy to cancer patient’s tumours. The current product in development, OncoSil™, is a locally implanted medical device that emits radiation into pancreatic tumours for up to three months.